IgEG Platform

hero-overlay

Combining IgE and IgG Functionality

  • Epsilogen has combined the powerful functionalities of IgE and IgG antibody isotypes
  • IgE and IgG are related but structurally/functionally different antibodies

IgEGs: Hybrid IgE/IgG Antibodies

By fusing the CH2-CH3 domains plus the hinge region of IgG to the C terminus of an IgE molecule to create an IgEG

IgEG antibodies have the potential for very high potency by:

  • Activating myeloid effector cells such as basophils and macrophages by binding IgE receptors
  • Activating Natural Killer (NK) cells by binding Fcg receptors
  • Fixing complement
  • Possessing extended serum half life by pH-dependent binding to FcRn

In vitro Proof of Concept established

  • Express well, fold correctly and bind antigen
  • Activate immune cells via engagement with Fcγ receptors
  • Activate immune cells via engagement with Fcε receptors
  • Bind to FcRn in pH-dependent fashion
    Drive both ADCC and ADCP responses

In vivo Proof of Concept established

  • NXG mouse/PBMC model with JIMT 1 cell challenge (HER2 low)
  • Anti-HER2 IgEGs showed statistically significant tumour growth inhibition (TGI)
  • IgEGs work at much lower doses than the equivalent IgG in the NXG mouse model

Half life extension demonstrated in transgenic mouse model

  • IgEGs possess greatly elevated serum half life versus IgE
  • IgEGs successfully combine long tissue half life of IgE with elevated serum half life of IgG
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.